Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817170 | 0.90 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL2196830 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL6095607 | 0.88 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6095615 | 0.88 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL27497514 | 0.87 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6821214 | 0.86 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6817276 | 0.85 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6817158 | 0.85 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6812883 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6651799 | 0.84 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | claimed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | claimed |
| EP-1210320-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | claimed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | disclosed |
| EP-1210320-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |